CytoDyn Inc. (OTCQB:CYDY) has announced the formation and the initial members of its Scientific Advisory Board, including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.
In a statement, Dr Scott A. Kelly, CytoDyn’s chief medical officer of CytoDyn said: "This team of advisors is passionately committed to bringing new treatment options to patients facing some of the world's most challenging health conditions including HIV, cancer, NASH, and rheumatological disorders. We are grateful to be working with such a distinguished group of medical and academic professionals."
READ: CytoDyn reaches patient quota for Phase 3 leronlimab coronavirus trial; analysis expected in four weeks
The late-stage biotechnology company said it's Scientific Advisory Board members include:
- Dr Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient
- Dr Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco
- Dr Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU)
- Dr Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHS
- Dr Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles
- Dr Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases;
- Dr Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network;
- D Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York
Kelly continued: "The combined years of medical practice, investigative trial experience and publications are more than impressive; we believe the collective wisdom and experience of these leaders will be the pathway to rapidly bringing leronlimab to the global health community.
"We will continue to expand this team with a focus on specific oncology indications, neurology, pulmonary and critical care, virology, and autoimmune diseases."
CytoDyn is developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.
Contact the author at [email protected]